RekrutujeFaza I/II
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Miasta: Bydgoszcz, Gdańsk, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: ZakończoneNa świecie: RekrutujeFaza I
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Miasta: Białystok, Gdańsk, Otwock, Siedlce i 1 inne miastoWiek: od 18 latSponsor: Nextcure Inc.
RekrutujeFaza I
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Miasta: Bydgoszcz, Gdańsk, Otwock, Poznań i 1 inne miastoWiek: od 18 latSponsor: Exelixis Inc.